Innovata plc (LSE: IOV) today announces that the FDA has issued a letter to the company indicating that ADEPT® adhesion reduction solution is approvable for use as an adjunct to good surgical technique for the reduction of post surgical adhesions in patients undergoing gynecological laparoscopic adhesiolysis.
